Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Vir Biotechnology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Vir Biotechnology's price to sales ratio was 7.3× on Nov 11, 2026, against 52.9× a year earlier. Over the last 5 years it ranged from 1.2× to 61.3×, with a median of 12.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.3× | −42.4 |
| 2025 | Dec 31, 2025 | 49.7× | +37.0 |
| 2024 | Dec 31, 2024 | 12.8× | +1.4 |
| 2023 | Dec 29, 2023 | 11.4× | +10.0 |
| 2022 | Dec 30, 2022 | 1.4× | −17.8 |
| 2021 | Dec 31, 2021 | 19.3× | −25.7 |
| 2020 | Dec 31, 2020 | 45.0× | +30.6 |
| 2019 | Dec 31, 2019 | 14.4× | – |
See a number that looks wrong?